1. Home
  2. USNA vs OMER Comparison

USNA vs OMER Comparison

Compare USNA & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • OMER
  • Stock Information
  • Founded
  • USNA 1992
  • OMER 1994
  • Country
  • USNA United States
  • OMER United States
  • Employees
  • USNA N/A
  • OMER N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • USNA Health Care
  • OMER Health Care
  • Exchange
  • USNA Nasdaq
  • OMER Nasdaq
  • Market Cap
  • USNA 648.2M
  • OMER 530.2M
  • IPO Year
  • USNA 1996
  • OMER 2009
  • Fundamental
  • Price
  • USNA $31.32
  • OMER $9.21
  • Analyst Decision
  • USNA Hold
  • OMER Buy
  • Analyst Count
  • USNA 1
  • OMER 4
  • Target Price
  • USNA $38.00
  • OMER $22.50
  • AVG Volume (30 Days)
  • USNA 123.0K
  • OMER 509.4K
  • Earning Date
  • USNA 02-25-2025
  • OMER 03-31-2025
  • Dividend Yield
  • USNA N/A
  • OMER N/A
  • EPS Growth
  • USNA N/A
  • OMER N/A
  • EPS
  • USNA 2.83
  • OMER N/A
  • Revenue
  • USNA $861,973,000.00
  • OMER N/A
  • Revenue This Year
  • USNA N/A
  • OMER N/A
  • Revenue Next Year
  • USNA $11.73
  • OMER N/A
  • P/E Ratio
  • USNA $11.08
  • OMER N/A
  • Revenue Growth
  • USNA N/A
  • OMER N/A
  • 52 Week Low
  • USNA $30.92
  • OMER $2.61
  • 52 Week High
  • USNA $52.75
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • USNA 31.12
  • OMER 49.57
  • Support Level
  • USNA $30.92
  • OMER $8.28
  • Resistance Level
  • USNA $36.25
  • OMER $9.08
  • Average True Range (ATR)
  • USNA 0.99
  • OMER 0.55
  • MACD
  • USNA -0.20
  • OMER -0.02
  • Stochastic Oscillator
  • USNA 14.63
  • OMER 56.45

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: